Introduction <p>Laparoscopic sleeve gastrectomy (LSG) has become a frequently employed primary bariatric procedure in recent years. Our objective was to evaluate the short- and mid-term outcomes of LSG with regard to weight reduction and its impact on associated comorbidities, particularly hypertension (HTN) and type 2 diabetes mellitus (T2DM).</p> Materials and Methods <p>86 patients who underwent LSG between June 2015 and December 2022 and whose postoperative 6-month, 1-year, and 3-year follow-up records were available were included in this retro-prospective study. Preoperative height/weight values, comorbidities, drugs used for HTN and/or T2DM, and changes in postoperative 6-month, 1-year, 3-year, and 5-year data were collected.</p> Results <p>compared to preoperative data, decrease in Body Mass Index (BMI) was statistically significant. Improvement in hypertension was seen in 46.6% of subjects and resolution in 53.4% of study subjects. Resolution in Diabetes was seen in 71% of subjects and improvement in 29% of study subjects.</p> Conclusion <p>Laparoscopic sleeve gastrectomy (LSG), when used as a primary surgical treatment for morbid obesity, is a highly effective and reliable procedure with low morbidity and mortality rates. Furthermore, it results in significant regression of associated comorbidities, such as hypertension and type 2 diabetes mellitus.</p>